QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 ...

Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...

The US Food and Drug Administration (FDA) has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic testing offerings in the US.

QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard ... The company serves more than 500,000 customers globally across Life Sciences and Molecular Diagnostics and employs over 5,700 people in over ...

About QIAGEN Certain statements in this press release ... commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers ...

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks ...